Loading clinical trials...
Loading clinical trials...
Collection of Human Blood for Development of Liquid Biopsy Assay
The purpose of this study is to develop a liquid biopsy approach for detection of circulating tumor cells (CTC) that could be used in place of the more invasive and potentially risky methods of tissue biopsy. The aims of the project are: (a) determine whether the Chaperonin-Containing TCP-1 (CCT) chaperonin can used to identify rare cancer cells in blood, and (b) establish whether the cancer cells detected using the CCT chaperonin for identification have invasive or metastatic potential.
Age
18 - 80 years
Sex
ALL
Healthy Volunteers
Yes
University of Central Florida
Orlando, Florida, United States
Start Date
October 7, 2021
Primary Completion Date
October 31, 2023
Completion Date
October 1, 2025
Last Updated
December 6, 2024
60
ESTIMATED participants
Lead Sponsor
University of Central Florida
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT02499458